Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Correctin myself.
Radio + chemo results are missing. Group sizes too. Hopefully in the next few days.
The risk I see is the FDA. Other than that Multikine did well. Ar first glance it seems to be a replacement for the SOC. The only downside it did not cross the anticipated threshold. But it is still better than SOC and without side effects. Am I missing something?
Let's wait for the data.
Multikine did better than SOC in all scenarios afaik. Simply, it did not meet the target in the scenario with the chemotherapy, which makes absolute sense. Multikine is incompatible with chemotherapy. This will be the case with all immunotherapy treatments, including DCvax from NWBO. Somehow I think this incompatibility has been overlooked when defining the case study and that is unfortunate.
Could you please share the infi source describing the groups? I was looking for exactly scuh information.
Tomorrow will be a good opportunity to buy more cheap shares :D
That means there is hope for another window to add more shares at sub 20.
Thanks for sharing your thoughts, Swegen. Looking forward to seeing how your forecast plays out next week!
Could you obtain a sample so we'd know what he ate?
I've just been looking for level 2 info. Is there free access to it anywhere? Anyone would recommend using interactive brokers' services for that?
Much appreciated Sushi for sharing your thoughts.
Better a month apart. I'd reinvest gains from one into the other one that's my naive and wishful thinking. Or would you advise to stay put until BO?
If you were to go all in, would it be CVM or NWBO? Just curious. Whichever way I look at them, it's even.
Please elaborate. Got out of the loop in the past couple of weeks.
Congrats!
Much appreciated lightrock.
Thanks sushi for sharing the ticker with us.
Just feeling bitter that I did not get in on Fri. Got so knackered at work that completely forgot about placing an order... Yet another bitter pill to swallow.
Last one was pulling out from BNGO at 0.5 just before the rise
Thanks!
What are the chances on aupha approval in your opinion, Sushi?
I have to admit I haven't done DD yet - just heard of it.
I would recommend subscribing to Cel-Sci mailing list and firgwt about the stock. Once this is approved (or not), you will receive the news. No more time and energy wasted.
I understand it's easier said than done, but give it a try. Helps
Understood. What I mean to say it is difficult to say whether the success rate of 90% for Ampion is good or bad without comparing to other drugs of the same class.
That said, even a 50% success rate might blow the stock price through.
You are comparing vaccine against anti-inflammatory medicine (apples and oranges, or apples and garlic moreso). I do not think this is a valid expectation.
Woth noting that in science a negative result is just as good result.
You can, for example, successfully defend a PhD thesis with a negative result.
I think it is responsible for a company to leave a record of an unsuccessful study to - that is a very valuable contribution to the field.
Don't forget, that here you are following a scientific process.
This scenario is certainly underisable
I think this has been discussed already... can't find the post(s). Suppose the results are unsatisfactory and the company is going belly up - any reason to hold up the results and form fillings? Is it possible at all or as others pointed out SEC would have already intervened?
Why is it important to maintain the stock price assuming the company has enough cash at hand and is going to deliver good results in the next 1-6 months?
Better this than a never ending FUD and fluctuations.
What percentage of success would you give? I mean a binary event - dcvax works and is approved or not. Gauging people's optimism
I think it's 75%.
Does it really matter though? The company is not here to satisfy small fish investor impatience. It's about releasing a product.
My opinion. Optimisatic target - Feb/March. That's a reasonable target date to publish an article given 1) they got data in Nov and 2) they are going to publish anything at all.
To be frank, I'm full of it right now.
Thanks, jimmy667, for explaining. That sounds like a good reason.
Contains numbers greater than the finger count on both hands.
I call this a baseless claim, a trigonometric fantasy.
If it costs $X to acquire a company, what does it matter whether you pay $X in cash or weigh in through shares worth the same $X?
Feels like a hassle to go through an extra step.
Upwards or downwards?
I think they can write it up e.g. a month. The data will dictate the structure and contents of the article. I doubt they can create a template with the placeholders and then simply fill in the values once they have been unblinded.
I am with you, VikingInvest. Imho, Provided they had been unblinded in November and submitted sometime in December we are looking at February/March as a good (and optimistic) target publication date.
Note, the Christmas time does help either.
There will be a number of peer reviewers, depending on a journal/conference the number may range from 3 to something like 9 or even more. Some of them may come back with "approved, no corrections required", some may complain about minor things such as typos, and others may request a more fundamental change/clarification on a number of subjects, resulting potentially in a rewrite or an addition of a whole section or sections or even an overhaul of the whole journal (LL is way too high profile for that to happen imho). Once resubmitted, peer reviewers will go through the journal again... Until everyone is happy.
The journal may be 10, 20, 30 pages long... Who knows.